Sudden severe abdominal pain, guarding, fever, and bleeding in a client receiving bevacizumab require emergency evaluation for gastrointestinal perforation. The nurse should stop or hold the drug, notify the provider urgently, keep the client NPO, support circulation, and prepare for imaging and surgical consultation. Bevacizumab labeling requires discontinuation when gastrointestinal perforation is diagnosed. Antidiarrheals, laxatives, heat, or delayed reassessment can worsen harm.
In-depth explanation
Clinical reasoning
VEGF inhibition impairs vascular and tissue repair and carries a serious risk of gastrointestinal perforation and fistula. Peritoneal findings are not routine diarrhea.
Decision rule
With suspected perforation during bevacizumab therapy, stop exposure, keep the client NPO, stabilize, and obtain urgent diagnostic and surgical evaluation.
Clinical scenario
Scenario A client receiving bevacizumab develops sudden severe abdominal pain, guarding, fever, and bloody stool.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.